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Abstract The side effects of oncological treatment,
which appear during or after therapy, are sometimes very
annoying for patients and are not adequately treated by
physicians. Among the symptoms experienced by breast
cancer patients are hot flushes, which result from a natural
or cancer therapy-induced menopause. The intensity of hot
flushes in breast cancer patients may be more severe than
those experienced by women undergoing a natural meno-
pause. Taking into account the incidence of breast cancer
and long-lasting hormone-suppression therapies, the prob-
lem of hot flushes will affect many women. Hormonal
replacement therapy, the most effective therapeutic means
for alleviating hot flushes, is usually contraindicated for
breast cancer patients. For intense and severe hot flushes,
pharmacological treatment using agents from a group of
selective serotonin reuptake inhibitors and serotonin and
norepinephrine reuptake inhibitors such as venlafaxine or
citalopram may be introduced. Other agents from different
pharmacological groups, such as clonidine, gabapentin, or
pregabalin, have also proved to be effective in treating hot
flushes. The efficacy of phytoestrogens has not been proven
in randomized clinical trials. The importance of the
placebo effect in decreasing vasomotor symptoms has also
been reported in many research papers. Educating breast
cancer patients in lifestyle changes which decrease the
frequency and intensity of vasomotor symptoms can offer
significant help too. This paper reviews the current state of
research in order to assess the options for the treatment of
hot flushes in breast cancer survivors.
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Introduction
In recent years, it has been observed that oncological
treatment has become increasingly successful, which is
reflected in the prolonged life expectancy of patients. The
side effects of oncological therapies which appear during
or after treatment seem not to be a problem that doctors are
fully aware of. One of the major oncological problems in
our society is breast cancer, with an incidence of 16,000
new cases per year in Poland (according to data from
2010). Nowadays, the peak incidence is between 50 and
69 years of age [1]. In this period, most women also
undergo the menopausal period, which is difficult for them,
as a consequence of the gradual decrease in gonadal
function with all its inherent complications. In females
treated for breast cancer who had regular menstrual cycles
before the oncological therapy, the premature menopause is
induced by chemotherapy and hormonotherapy.
Due to the increase in the incidence of breast cancer, the
aging of the Polish population, and the tendency of pro-
longing the time of hormonotherapy even up to 10 years, it
can also be assumed that an increasing number of patients
are suffering from menopausal symptoms. One of the
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characteristic menopausal symptoms (apart from the ces-
sation of menstrual cycles) is vasomotor symptom. The
term vasomotor symptoms or hot flushes defines the sub-
jective sensation of sudden heat, which is usually most
intense over the face, neck, and chest. Hot flushes are often
accompanied by a reddening of the face, followed by
intensive sweating and even chills. Palpitations, anxiety,
and night sweats are also very frequent symptoms. The
duration of the symptoms, their frequency, and intensity
depend on the individual predispositions of females. In a
general population, hot flushes occur in even 75 % of
menopausal women [2, 3]. These symptoms interfere with
daily life and have a detrimental effect on its quality.
The pathogenesis of hot flushes
Despite intensive research conducted for many years, the
pathophysiology of hot flushes still remains unclear. It
seems that the dysfunction of the thermoregulatory center,
which is located in the preoptic area of the hypothalamus,
plays a key role in this mechanism. The thermoregulatory
center maintains the core body temperature within certain
homeostasis defined by thermoregulatory thresholds.
Sweating occurs when the core temperature of the body
increases above the upper threshold of the thermoregula-
tory zone, whereas chills occur when the core temperature
falls below the lower threshold of the thermoregulatory
zone [4]. Freedman’s research revealed that women who
experience hot flushes had a narrower thermoregulatory
zone, which led to a greater likelihood of crossing these
thresholds and developing vasomotor symptoms. Increas-
ing estrogen deficiency in the menopausal period, which
interferes with the hypothalamic regulatory systems func-
tioning with the use of norepinephrine, serotonin, testos-
terone, and endorphins, may also contribute to disturbances
in the homeostasis of the thermoregulatory center. The
result of these interactions triggers the process of hot flu-
shes with the response of the autonomic nervous system
and the releasing of hormones [4–6].
Vasomotor symptoms in women treated due
to breast cancer
The oncologic treatment of patients with breast cancer is
multidisciplinary and consists of surgical procedure (breast
conserving therapy or a radical mastectomy) and adjuvant
treatment which includes radiotherapy and systemic ther-
apy. The systemic therapy is individually designed for the
patient depending on the subtype of the breast cancer and
the clinical and pathologic features of the disease [7].
Chemo- and hormonal therapies induce side effects which
include, among others, a premature menopause with its
consequences. The incidence of cancer therapy-induced
menopause depends on the patients’ age, the model of
multi-drug chemotherapy, and its cumulative dose [4, 8]. In
2010, Mar Fan published the results of a prospective study
which compared the menopausal symptoms in two groups
of patients. One group consisted of patients with a
chemotherapy-induced menopause and the second group
included women who had gone through a natural meno-
pause. The study confirmed that breast cancer patients
experienced significantly more moderate/severe hot flushes
than control women undergoing a natural menopause (51
vs 19 %) [9]. In the therapy of breast cancer, which is a
hormone dependent cancer, tamoxifen and a group of drugs
called aromatase inhibitors (AI) hold a very important
position. The indication for the use of these drugs is the
confirmed expression of steroid receptors in the cancer
cells. Tamoxifen can be applied in all breast cancer patients
at every stage of cancer therapy and also as a prophylaxis.
Tamoxifen belongs to the group of agents which are called
selective estrogen receptor modulators (SERM) and exerts
its antineoplastic action by blocking estrogen receptors
(ER) in cancer cells. In this way, tamoxifen prevents the
interaction of endogenous estrogens with ER. In post-
menopausal females, estradiol is synthesized almost
exclusively in peripheral tissues from the conversion of
androstenedione to estrone with the use of aromatase. The
mechanism of the action of AI in the treatment of post-
menopausal patients is to inhibit peripheral estrogen syn-
thesis [10].
The clinical trials evaluating tamoxifen revealed that
even up to 80 % of females experienced hot flushes during
therapy with this agent, and 30 % of patients defined these
symptoms as severe [3]. Despite the high efficacy of
tamoxifen, the harmful side effects have been identified in
previous studies as a significant reason for not persisting
with treatment for 16–30 % of breast cancer patients [11].
AI used in postmenopausal patients also induce vasomotor
symptoms. In randomized trials comparing the efficacy of
AI with tamoxifen, it has been revealed that hot flushes
induced by AI were less severe. In an ATAC study, 35.7 %
of patients treated with anastrozole experienced vasomotor
symptoms in comparison to 40.9 % of patients treated with
tamoxifen. Similarly, in BIG 1–98 study, 33.5 % of
females taking letrozole suffered hot flushes compared to
38 % of patients treated with tamoxifen [12].
Hormonal replacement therapy and breast cancer
Hormonal replacement therapy (HRT) is the most efficient
means for alleviating menopausal symptoms, not only hot
flushes [10]. Many trials have been carried out evaluating
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HRT in healthy postmenopausal women. One of them was
the big American randomized trial, the Women’s Health
Initiative (WHI), which assessed the benefits of estrogen
plus progestin therapy among healthy postmenopausal
women in comparison to the placebo group. The results of
the WHI demonstrated a 26 % increase in the risk of breast
cancer in the group treated with HRT compared to those
diagnosed in the placebo group [13]. The increased risk of
breast cancer in healthy postmenopausal women treated
with HRT was also revealed in the Million Women Study.
It was confirmed that the risk of breast cancer was
dependent on the duration of the treatment and the type of
HRT used [14].
Trials have been also conducted addressing the issue
whether HRT is safe for women who have previously had
breast cancer. One of them is the Swedish randomized trial,
the hormone replacement therapy after breast cancer
(HABITS), which was stopped when the initial analysis
revealed a doubly increased risk of recurrence after hor-
mone replacement therapy in breast cancer survivors (lo-
coregional recurrence, distant metastases, or cancer of the
opposite breast). After extended follow-up, there was sig-
nificantly increased risk of new breast cancer occurring in
women who took HRT in comparison to the placebo group
(22.2 vs 8 %, respectively) [15]. After the results of the
HABIT trial, the second Swedish randomized trial—
Stockholm trial was also stopped in 2003, even though the
initial analyses showed no increased risk of breast cancer
recurrence among women taking HRT [16]. Data from the
10-year follow-up to the Stockholm randomized trial are
currently available. The authors of the paper demonstrated
that in both studies among women on HRT, no increased
mortality due to breast cancer or other malignancies was
found. The increased recurrence in HABITS has been
attributed to higher progestin exposure [17]. However, the
negative relationship between HRT and breast cancer has
been confirmed in many trials. These studies concerned
both combined HRT and only estrogen or progestational
agents. In conjunction with these results, HRT is con-
traindicated in females after breast cancer therapy [4, 18].
Pharmacological treatment
Antidepressants agents: SSRIs and SNRIs
Selective serotonin reuptake inhibitors (SSRIs) and sero-
tonin and norepinephrine reuptake inhibitors (SNRIs) are
the classes of drugs which are used for hot flushes therapy
in breast cancer patients and their efficacy has been proven
in randomized clinical trials [3, 18].
A daily dose of 10 mg of paroxetine, 20 mg of fluox-
etine, and 10–20 mg of citalopram all belong to SSRIs,
which have a great body of evidence for their beneficial
effect in the treatment of hot flushes. Venlafaxine, rec-
ommended with a daily dose from 37.5 to 75 mg, is
believed to be the most important agent in the group of
SSRIs. The use of venlafaxine has been evaluated in five
randomized clinical trials: in two placebo-controlled trials
and in three trials with clonidine.
Studies show that the use of SSRIs and SNRIs signifi-
cantly reduced the frequency and severity of hot flushes in
breast cancer patients by 14–58 % in comparison to the
placebo. However, the most common side effects caused
by these drugs include dry mouth, headaches, constipation,
nausea, and loss of appetite [18].
What is more, SSRIs and SNRIs are inhibitors of the
cytochrome P450 2D (CYP2D6) pathway, an important
enzyme which metabolizes tamoxifen to its active form—
endoxifen. Fluoxetine and paroxetine are strong
P450(CYP)2D6 inhibitors and these drugs significantly
decrease plasma endoxifen concentration and should not
be administered along with tamoxifen [18–20]. Citalo-
pram is considered to be a much weaker P450(CYP)2D6
inhibitor, which gives only a slight decrease in plasma
endoxifen concentration, which is probably of no clinical
relevance [3]. Venlafaxine also turned out to be a weak
P450(CYP)2D6 inhibitor. The data show no influence on
endoxifen concentration in patients taking tamoxifen. In
conclusion, venlafaxine may be used in the treatment of
hot flushes in breast cancer patients taking tamoxifen
[3, 18].
Other drugs
Clonidine, an antihypertensive agent, has been reported as
effective in the treatment of hot flashes in postmenopausal
women based on a daily dose 0.1 mg [21].
In randomized clinical trials, the efficacy of antiepileptic
agents such as gabapentin and pregabalin has also been
proven. The recommended initial daily dose of gabapentin
of 300 mg, gradually increased to 900 mg, and pregabalin
with a dose of 50–150 mg, resulted in a significant
reduction in the frequency of hot flushes [3, 18].
It has been reported that a dose of 400 IU of vitamin E
twice daily may have a marginally beneficial influence on
treating hot flushes [3, 22].
Phytoestrogens
Phytoestrogens are plant-derived compounds, closely
related to steroids—phytosterols and isoflavones. In their
structure, phytoestrogens are similar to the female steroid
hormones produced by the ovaries and adrenal glands, and
they cause both estrogenic and antiestrogenic activity in the
human body. The main source of phytoestrogens and
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isoflavones in a diet is soy, chickpeas, mung beans, and
alfalfa sprouts. These compounds can also be found in
small amounts in cereals, rice, onions, and garlic. Lignans,
which are present in flax seeds, sunflower seeds, olives,
cherries, sesame seed oil, garlic, and tea, also show weak
estrogen properties [23]. The efficacy of phytoestrogens in
hot flushes treatment in breast cancer patients has been
studied in many randomized clinical trials. These studies
compared the efficacy of different formulas containing
various phytoestrogens and isoflavons, including soya and
flaxseed products with the placebo. None of these trials
demonstrated the superiority of phytoestrogens in reducing
hot flushes in comparison to the placebo [24–28]. Temp-
fer’s metaanalysis assessed the side effects caused by
phytoestrogens used in the menopausal period for the
treatment of climacteric syndrome. The authors revealed,
comparing the treatment with the placebo, that phytoe-
strogens are safe but may moderately elevate rates of
gastrointestinal side effects [29].
In alternative medicine, black cohosh is recommended
as a natural treatment for menopausal symptoms. Current
studies conducted in breast cancer patients treated with
black cohosh reveal that black cohosh were not effective in
reducing hot flushes in this group of females. The available
data also do not support an association between black
cohosh and an increased risk of breast cancer, as was
suggested in previous observations [30].
What is interesting is that in many clinical trials con-
trolled with a placebo, a substantial placebo effect has been
shown in the treatment of hot flushes. It has been demon-
strated that the placebo effect can reduce hot flushes by
even 50 %. Therefore, the placebo effect should be always
seriously taken into account [12].
Patient education
Informing the cancer patients of both the side effects of the
therapy as well as the methods of their prevention plays a
crucial role in the work of healthcare professionals. In the
literature, the emphasis has been on the importance of
patient education in life style changes, which decrease the
frequency and feeling of vasomotor symptoms. Avoiding
all situations which can trigger hot flushes has been sug-
gested, including such triggers as stress, caffeine, hot spi-
ces, hot rooms, and hot baths. It has been also advised that
patients should maintain a low core body temperature
through dressing in layers, consuming cool drinks and
food, and using a fan as needed. Stopping smoking,
maintaining a healthy weight (BMI up to 27 kg/m2), reg-
ular physical activity, and relaxation techniques are also
very important [3, 4, 31, 32].
Conclusions
In recent years, numerous studies have been carried out on
the efficacy of pharmacological and nonpharmacological
methods of treatment of vasomotor symptoms in the course
of a natural or breast cancer chemo- or hormonotherapy-
induced menopause. Menopausal symptoms, including hot
flushes, are reported by the majority of breast cancer
patients and they contribute to a poor quality of life. Taking
into account the increasing incidence of breast cancer and
existing indications for extended treatment with tamoxifen,
this problem will affect more and more breast cancer sur-
vivors. For severe hot flushes, the above mentioned phar-
macological treatment may be introduced. What is
important is that the approach to the patients should always
be individually designed, after a careful assessment of the
benefits and side effects of the therapy being suggested. All
the patients should be educated on the simple but effective
methods of minimizing the intensity and frequency of hot
flushes symptoms in everyday life.
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